Midfacial Product Selection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03381040
Recruitment Status : Completed
First Posted : December 21, 2017
Last Update Posted : January 10, 2019
Information provided by (Responsible Party):
Erevna Innovations Inc.

Brief Summary:
This study seeks to determine whether patients pursuing injectable treatments for facial volume loss and/or contour deficiency can be separated into strata based on characteristics such as skin envelope and subcutaneous tissue quantity in the zygomatic, submalar and anteromedial cheek regions in order to guide the clinician in making the ideal product choice (i.e., Restylane Volyme vs Lyft)?

Condition or disease Intervention/treatment Phase
Facial Volume Loss Device: Restylane Lyft Device: Restylane Volyme Phase 4

Detailed Description:

With age, loss of facial fat and hollowing of the cheeks can result in a "sinking" appearance in the mid-face. Augmentation and contouring of the area can be corrected using dermal fillers such as Restylane.

Currently, product choice and amount of volume used for injectable procedures varies between physicians as there is no standard for treatment. Individual assessment based on the attending physician's preference and experience determines final product selection and technique. An algorithm is needed to standardize best practices between physicians and clinics and to better regulate the use of dermal fillers in facial plastic surgery.

Therefore, the purpose of this study is to is to develop an algorithm to decide on which product (i.e., Restylane Volyme or Lyft) to use in the cheek area based on subject characteristics such as age, skin quality, subcutaneous fat quantity and positioning, and bony structure.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Predictive Algorithm for Product Selection in the Management of Mid Facial Volume Correction: Part I - A Pilot Validation of Patient Strata
Actual Study Start Date : December 5, 2017
Actual Primary Completion Date : August 15, 2018
Actual Study Completion Date : January 8, 2019

Arm Intervention/treatment
Active Comparator: Group A
Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
Device: Restylane Lyft
Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.

Active Comparator: Group B
Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
Device: Restylane Volyme

Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.

Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope.

Primary Outcome Measures :
  1. Comparison of two Restylane products to treat mid-face/cheek deformities. [ Time Frame: Baseline and Week 16. ]
    Investigators will evaluate whether a difference in physician assessed efficacy as per the standardized photos between two Restylane products at 16 weeks (visit 5) in comparison to baseline (visit 1) using the GAIS scale.

Secondary Outcome Measures :
  1. Standardized Imagery for the Improvement of Mid-face Hollowing [ Time Frame: Baseline to week 8 ]
    Investigators will evaluate whether an aesthetic change in mid-face contour is observed at visit 3 (4 weeks), and visit 4 (8 weeks) compared to Baseline. The change in mid-face shape will be assessed using the standardized photographs.

  2. Patient satisfaction questionnaire [ Time Frame: Baseline to 16 weeks ]
    Patients will rate their overall satisfaction with treatment results using the patient satisfaction questionnaire at visits 2, 3, 4 and 5. The questionnaire is a 5-point scale comprising 'extremely satisfied', 'satisfied', 'slightly satisfied', 'dissatisfied', and 'extremely satisfied'.

  3. Global aesthetic improvement scale [ Time Frame: Baseline to 16 weeks ]
    Physicians will rate the overall improvement since injection using the Global Aesthetic Improvement Scale at visits 2, 3, 4 and 5. The scale is a 5-point scale comprising 'very much improved', 'much improved', 'improved', 'no change', and 'worse'.

  4. Medicis Mid-face Volume Scale [ Time Frame: Baseline to 16 weeks ]
    At visits 2, 3, 4 and 5, a blinded reviewer will rate each patient's hemiface using the MMVS. The MMVS is a four-point scale that measures the amount of mid-face volume loss comprising of "fairly full", "mild loss", "moderate loss" and "substantial loss". MMVS response rate, defined as the percentage of subjects with at least a 1-grade improvement in MMVS from Baseline up to Week 16 after treatment, will be used in the analyses.

  5. Standardized Ultrasonography Images [ Time Frame: Baseline to 16 weeks ]
    Ultrasound images will be taken before and after injections at the Baseline visit, and all subsequent follow up visits. At Visit 1, the images will be used to determine skin thickness and ascertain the site (e.g., dermis, subcutaneous region) of filler injected into the soft tissue of the face. At follow up visits, ultrasound images will be used to delineate whether the amount of filler has decreased between visits. The analyses of the sonographic characteristics of the fillers will allow for optimization of treatment results.

Other Outcome Measures:
  1. Adverse events [ Time Frame: Baseline to 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. At the time of consent, women between the ages of 30 and 75 years old;
  2. Patients with established mid-face/cheek hollowing;
  3. Patients with a MMVS score of 2 or 3 at baseline;
  4. Accepted the obligation not to receive any other facial procedures through the 4-month follow-up;
  5. Understood and accepted the obligation and would be logistically able to appear for all scheduled follow-up visits;
  6. No previous facial fillers for a period of 12 months prior to this study;
  7. No previous facial fillers in the mid-face for 18 months prior to this study;
  8. Capable of providing informed consent.

Exclusion Criteria:

  1. Current Pregnancy or lactation [sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)].;
  2. Hypersensitivity to Restylane products, hyaluronic acid filler or amide local anesthetics;
  3. Patients presenting with porphyria;
  4. Inability to comply with follow-up and abstain from facial injections during the study period;
  5. Heavy smokers, classified as smoking more than 12 cigarettes per day;
  6. History of severe or multiple allergies manifested by anaphylaxis;
  7. Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion;
  8. Previous surgery including aesthetic facial surgical therapy or liposuction, piercing, or tattoos in the treatment area;
  9. History or presence of any disease or lesion near or at the treatment area, including inflammation, active or chronic infection, including in the mouth, dentals, head and neck region;
  10. Facial psoriasis, eczema, acne, rosacea, perioral dermatitis and herpes zoster;
  11. Scars or deformities;
  12. Cancer or precancer, e.g. actinic keratosis;
  13. History of radiation therapy to the treatment area;
  14. History of bleeding disorders or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid anti-inflammatory drugs [NSAIDs]), within 2 weeks before treatment;
  15. Patients using immunosuppressants;
  16. Patients with a tendency to form hypertrophic scars or any other healing disorders;
  17. Patients with known hypersensitivity to lidocaine or agents structurally related to amide type local anaesthetics (e.g., certain anti-arrhythmics);
  18. Patients administered dental block or topical administration of lidocaine;
  19. Patients with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.
  20. Skin thickness between 1.2mm and 1.49mm (as determined by ultrasound).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03381040

Canada, Quebec
Victoria Park Clinical Research Centre
Westmount, Quebec, Canada, H3Z1C3
Sponsors and Collaborators
Erevna Innovations Inc.
Principal Investigator: Andreas Nikolis, MD Erevna Innovations Inc.

Responsible Party: Erevna Innovations Inc. Identifier: NCT03381040     History of Changes
Other Study ID Numbers: 2017-01-001G
First Posted: December 21, 2017    Key Record Dates
Last Update Posted: January 10, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents